Wells Fargo dispatches biotech banker to Cambridge/Boston supercluster

With the Cambridge/Boston biotech supercluster forming a kind of global crossroads for drug development, bankers are going the extra mile to get in on the act. In Wells Fargo's case, it's going an extra 3,000 miles out of its way. Wells Fargo life sciences specialist Katherine Andersen is uprooting herself from Palo Alto, CA, to make the trek to Boston. "It's challenging to grow relationships from 3,000 miles away," Andersen told the Boston Globe. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.